blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2578229

EP2578229 - Decreasing potential iatrogenic risks associated with vaccine antigens [Right-click to bookmark this link]
StatusPatent revoked
Status updated on  20.11.2020
Database last updated on 09.07.2024
FormerThe patent has been granted
Status updated on  11.04.2017
Most recent event   Tooltip20.11.2020Revocation of patentpublished on 23.12.2020  [2020/52]
Applicant(s)For all designated states
Novartis Vaccines and Diagnostics GmbH
Emil-von-Behring-Strasse 76
35041 Marburg / DE
[2013/15]
Inventor(s)01 / Gregersen, Jens Peter
Novartis Vaccines and Diagnostics GmbH
Emil-von-Behring Strasse 76
35041 Marburg / DE
 [2013/15]
Representative(s)Carpmaels & Ransford LLP
One Southampton Row
London WC1B 5HA / GB
[N/P]
Former [2013/15]Carpmaels & Ransford
One Southampton Row
London WC1B 5HA / GB
Application number, filing date12193096.009.09.2005
[2013/15]
Priority number, dateEP2004025547109.09.2004         Original published format: EP 04255471
[2013/15]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP2578229
Date:10.04.2013
Language:EN
[2013/15]
Type: B1 Patent specification 
No.:EP2578229
Date:10.07.2013
Language:EN
[2013/28]
Search report(s)(Supplementary) European search report - dispatched on:EP08.03.2013
ClassificationIPC:A61K39/145, C12Q1/70
[2013/15]
CPC:
A61K39/145 (EP,US); C12N7/00 (US); A61K39/12 (EP,US);
A61P31/12 (EP); A61P31/16 (EP); A61P37/04 (EP);
C12Q1/70 (US); C12Q1/701 (US); G01N33/56983 (US);
C12N2760/16034 (US); C12N2760/16051 (EP,US); C12N2760/16134 (EP,US);
C12N2760/16234 (EP,US); G01N2333/11 (US); Y02A50/30 (EP,US) (-)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   NL,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2013/15]
Extension statesAL22.03.2013
BA22.03.2013
HR22.03.2013
MK22.03.2013
YU22.03.2013
TitleGerman:Verringerung potentieller iatrogener, mit Impfstoffen zusammenhängender Risiken[2013/15]
English:Decreasing potential iatrogenic risks associated with vaccine antigens[2013/15]
French:Diminution des risques iatrogéniques potentiels associés aux vaccins[2013/15]
Examination procedure30.11.2012Examination requested  [2013/15]
18.04.2013Amendment by applicant (claims and/or description)
29.05.2013Communication of intention to grant the patent
30.05.2013Fee for grant paid
30.05.2013Fee for publishing/printing paid
Parent application(s)   TooltipEP05795012.3  / EP1789084
EP10075310.2  / EP2236155
EP12157945.2  / EP2471551
Opposition(s)Opponent(s)01  09.04.2014  14.04.2014  ADMISSIBLE
SANOFI PASTEUR SA
2 Avenue Pont Pasteur
69007 Lyon / FR
Opponent's representative
Cabinet Beau de Loménie, et al, et al
51 avenue Jean Jaurès
BP 7073
69301 Lyon Cedex 07 / FR
 02  10.04.2014  22.04.2014  ADMISSIBLE
Intervet International BV
Wim de Körverstraat 35
5831 AN Boxmeer / NL
Opponent's representative
Intervet International B.V.
Wim de Körverstraat 35
5831 AN Boxmeer / NL
 03  10.04.2014  23.04.2014  ADMISSIBLE
Merck Sharp & Dohme Corp.
126 East Lincoln Avenue
Rahway, NJ 07065 / US
Opponent's representative
Böhles, Elena
Merck Sharp & Dohme Corp.
120 Moorgate
London, EC2M 6UR / GB
 [N/P]
Former [2020/03]
Opponent(s)01  09.04.2014  14.04.2014  ADMISSIBLE
SANOFI PASTEUR SA
2 Avenue Pont Pasteur
69007 Lyon / FR
Opponent's representative
Cabinet Beau de Loménie, et al, et al
51 avenue Jean Jaurès
BP 7073
69301 Lyon Cedex 07 / FR
 02  10.04.2014  22.04.2014  ADMISSIBLE
Intervet International BV
Wim de Körverstraat 35
5831 AN Boxmeer / NL
Opponent's representative
Intervet International B.V.
Wim de Körverstraat 35
5831 AN Boxmeer / NL
 03  10.04.2014  23.04.2014  ADMISSIBLE
Merck Sharp & Dohme Corp.
126 East Lincoln Avenue
Rahway, NJ 07065 / US
Opponent's representative
Böhles, Elena
Merck & Co., Inc.
Hertford Road
Hoddesdon, Hertfordshire EN11 9BU / GB
Former [2017/16]
Opponent(s)01  09.04.2014  14.04.2014  ADMISSIBLE
SANOFI PASTEUR SA
2 Avenue Pont Pasteur
69007 Lyon / FR
Opponent's representative
Sarlin, Laure V., et al, et al
Cabinet Beau de Loménie
51, avenue Jean-Jaurès
BP 7073
69301 Lyon Cedex 07 / FR
 02  10.04.2014  22.04.2014  ADMISSIBLE
Intervet International BV
Wim de Körverstraat 35
5831 AN Boxmeer / NL
Opponent's representative
Intervet International B.V.
Wim de Körverstraat 35
5831 AN Boxmeer / NL
 03  10.04.2014  23.04.2014  ADMISSIBLE
Merck Sharp & Dohme Corp.
126 East Lincoln Avenue
Rahway, NJ 07065 / US
Opponent's representative
Böhles, Elena
Merck & Co., Inc.
Hertford Road
Hoddesdon, Hertfordshire EN11 9BU / GB
Former [2015/49]
Opponent(s)01  09.04.2014  14.04.2014  ADMISSIBLE
SANOFI PASTEUR SA
2 Avenue Pont Pasteur
69007 Lyon / FR
Opponent's representative
Sarlin, Laure V., et al, et al
Cabinet Beau de Loménie
51, avenue Jean-Jaurès
BP 7073
69301 Lyon Cedex 07 / FR
 02  10.04.2014  22.04.2014  ADMISSIBLE
Intervet International BV
Wim de Körverstraat 35
5831 AN Boxmeer / NL
Opponent's representative
Claessens, John
MSD Animal Health
Intellectual Property Group
Wim de Körverstraat 35
5831 AN Boxmeer / NL
 03  10.04.2014  23.04.2014  ADMISSIBLE
Merck Sharp & Dohme Corp.
126 East Lincoln Avenue
Rahway, NJ 07065 / US
Opponent's representative
Böhles, Elena
Merck & Co., Inc.
Hertford Road
Hoddesdon, Hertfordshire EN11 9BU / GB
Former [2014/21]
Opponent(s)01  09.04.2014  14.04.2014  ADMISSIBLE
SANOFI PASTEUR SA
2 Avenue Pont Pasteur
69007 Lyon / FR
Opponent's representative
Schaeffer, Nathalie Christiane, et al, et al
Sanofi Pasteur 2, avenue Pont Pasteur
69367 Lyon Cedex 07 / FR
 02  10.04.2014   
Intervet International BV
Wim de Körverstraat 35
5831 AN Boxmeer / NL
Opponent's representative
Claessens, John
MSD Animal Health
Intellectual Property Group
Wim de Körverstraat 35
5831 AN Boxmeer / NL
 03  10.04.2014    ADMISSIBLE
Merck Sharp & Dohme Corp.
126 East Lincoln Avenue
Rahway, NJ 07065 / US
Opponent's representative
Böhles, Elena
Merck & Co., Inc.
Hertford Road
Hoddesdon, Hertfordshire EN11 9BU / GB
Former [2014/20]
Opponent(s)01  09.04.2014   
SANOFI PASTEUR SA
2 Avenue Pont Pasteur
69007 Lyon / FR
Opponent's representative
Schaeffer, Nathalie Christiane, et al, et al
Sanofi Pasteur 2, avenue Pont Pasteur
69367 Lyon Cedex 07 / FR
15.05.2014Invitation to proprietor to file observations on the notice of opposition
20.10.2014Reply of patent proprietor to notice(s) of opposition
19.01.2017Date of oral proceedings
12.04.2017Despatch of minutes of oral proceedings
12.04.2017Despatch of communication that the patent will be revoked
26.10.2020Legal effect of revocation of patent [2020/52]
Appeal following opposition20.06.2017Appeal received No.  T1392/17
22.08.2017Statement of grounds filed
26.10.2020Result of appeal procedure: appeal of the proprietor withdrawn
Fees paidRenewal fee
16.11.2012Renewal fee patent year 03
16.11.2012Renewal fee patent year 04
16.11.2012Renewal fee patent year 05
16.11.2012Renewal fee patent year 06
16.11.2012Renewal fee patent year 07
16.11.2012Renewal fee patent year 08
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipCY10.07.2013
EE10.07.2013
LT10.07.2013
LV10.07.2013
MC10.07.2013
IS10.11.2013
FI09.09.2014
LU09.09.2014
RO09.09.2014
HU10.09.2014
SE10.09.2014
GR03.04.2015
PT09.06.2015
SK09.09.2015
SI10.09.2015
BG08.08.2017
[2019/29]
Former [2019/10]CY10.07.2013
EE10.07.2013
LT10.07.2013
LV10.07.2013
MC10.07.2013
TR10.07.2013
IS10.11.2013
FI09.09.2014
LU09.09.2014
RO09.09.2014
HU10.09.2014
SE10.09.2014
GR03.04.2015
PT09.06.2015
SK09.09.2015
SI10.09.2015
BG08.08.2017
Former [2017/40]CY10.07.2013
EE10.07.2013
LT10.07.2013
LV10.07.2013
MC10.07.2013
TR10.07.2013
IS10.11.2013
FI09.09.2014
LU09.09.2014
RO09.09.2014
HU10.09.2014
SE10.09.2014
GR03.04.2015
PT09.06.2015
SK09.09.2015
SI10.09.2015
BG30.09.2015
Former [2016/36]CY10.07.2013
EE10.07.2013
LT10.07.2013
LV10.07.2013
MC10.07.2013
TR10.07.2013
IS10.11.2013
FI09.09.2014
LU09.09.2014
RO09.09.2014
HU10.09.2014
SE10.09.2014
GR03.04.2015
PT09.06.2015
SK09.09.2015
SI10.09.2015
Former [2015/39]CY10.07.2013
EE10.07.2013
LT10.07.2013
LV10.07.2013
MC10.07.2013
TR10.07.2013
IS10.11.2013
FI09.09.2014
LU09.09.2014
RO09.09.2014
HU10.09.2014
SE10.09.2014
GR03.04.2015
PT09.06.2015
Former [2015/37]CY10.07.2013
EE10.07.2013
LT10.07.2013
LV10.07.2013
MC10.07.2013
TR10.07.2013
IS10.11.2013
FI09.09.2014
LU09.09.2014
RO09.09.2014
SE10.09.2014
GR03.04.2015
PT09.06.2015
Former [2015/35]CY10.07.2013
EE10.07.2013
LT10.07.2013
LV10.07.2013
MC10.07.2013
TR10.07.2013
IS10.11.2013
FI09.09.2014
LU09.09.2014
RO09.09.2014
SE10.09.2014
PT09.06.2015
Former [2015/32]CY10.07.2013
EE10.07.2013
LT10.07.2013
LV10.07.2013
MC10.07.2013
TR10.07.2013
IS10.11.2013
FI09.09.2014
LU09.09.2014
RO09.09.2014
SE10.09.2014
Former [2015/24]CY10.07.2013
EE10.07.2013
LT10.07.2013
LV10.07.2013
MC10.07.2013
IS10.11.2013
FI09.09.2014
LU09.09.2014
RO09.09.2014
SE10.09.2014
Former [2015/23]CY10.07.2013
EE10.07.2013
LT10.07.2013
LV10.07.2013
MC10.07.2013
IS10.11.2013
FI09.09.2014
LU09.09.2014
RO09.09.2014
Former [2015/22]CY10.07.2013
EE10.07.2013
LT10.07.2013
LV10.07.2013
MC10.07.2013
IS10.11.2013
LU09.09.2014
RO09.09.2014
Former [2014/23]CY10.07.2013
EE10.07.2013
LT10.07.2013
LV10.07.2013
MC10.07.2013
IS10.11.2013
Former [2014/20]CY10.07.2013
LT10.07.2013
LV10.07.2013
MC10.07.2013
IS10.11.2013
Former [2014/18]CY10.07.2013
LT10.07.2013
LV10.07.2013
IS10.11.2013
Former [2014/12]LT10.07.2013
LV10.07.2013
CY18.09.2013
IS10.11.2013
Former [2014/10]LT10.07.2013
CY18.09.2013
IS10.11.2013
Former [2014/08]LT10.07.2013
Documents cited:Search[X]  - KWEON C-H ET AL, "Derivation of attenuated porcine epidemic diarrhea virus (PEDV) as vaccine candidate", VACCINE, ELSEVIER LTD, GB, (19990604), vol. 17, no. 20-21, doi:10.1016/S0264-410X(99)00059-6, ISSN 0264-410X, pages 2546 - 2553, XP004169664 [X] 1-9 * page 2547, column l, paragraph 1 *

DOI:   http://dx.doi.org/10.1016/S0264-410X(99)00059-6
 [X]  - O-W MERTEN, "Virus contaminations of cell cultures - A biotechnological view", CYTOTECHNOLOGY, KLUWER ACADEMIC PUBLISHERS, DO, (20020601), vol. 39, no. 2, doi:10.1023/A:1022969101804, ISSN 1573-0778, pages 91 - 116, XP019236736 [X] 1-9 * tables 8, 9 * * page 104, column r, paragraph l - page 105, column l, paragraph 4 *

DOI:   http://dx.doi.org/10.1023/A:1022969101804
 [Y]  - HORAUD F, "Absence of viral sequences in the WHO-Vero Cell Bank. A collaborative study", DEVELOPMENTS IN BIOLOGICAL STANDARDIZATION, KARGER, BASEL, CH, (19920101), vol. 76, ISSN 0301-5149, pages 43 - 46, XP009159105 [Y] 1-9 * table 2 *
 [Y]  - JACKWOOD D H ET AL, "REPLICATION OF INFECTIOUS BURSAL DISEASE VIRUS IN CONTINUOUS CELL LINES", AVIAN DISEASES, (1987), vol. 31, no. 2, ISSN 0005-2086, pages 370 - 375, XP009167506 [Y] 1-9 * page 374, column l, paragraph 1 *

DOI:   http://dx.doi.org/10.2307/1590888
 [XP]  - MONATH T P ET AL, "ACAM2000 clonal Vero cell culture vaccinia virus (New York City Board of Health strain) - a second-generation smallpox vaccine for biological defense", INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, INTERNATIONAL SOCIETY FOR INFECTIOUS DISEASES, HAMILTON, CA, vol. 8, ISSN 1201-9712, (20041001), pages 31 - 44, (20041103), XP027477980 [XP] 1-9 * the whole document *
by applicantUS5292506
 WO9419013
 WO9615231
 EP0721782
 WO9737000
 US5948410
 WO0122992
 US6372223
 WO02097072
 US6534065
 WO03076601
 WO2005042728
    - BRANDS ET AL., DEV BIOL STAND, (1999), vol. 98, pages 93 - 100
    - HALPERIN ET AL., VACCINE, (2002), vol. 20, pages 1240 - 7
    - TREE ET AL., VACCINE, (2001), vol. 19, pages 3444 - 50
    - KISTNER ET AL., VACCINE, (1998), vol. 16, pages 960 - 8
    - KISTNER ET AL., DEV BIOL STAND, (1999), vol. 98, pages 101 - 110
    - BRUHL ET AL., VACCINE, (2000), vol. 19, pages 1149 - 58
    - PAU ET AL., VACCINE, (2001), vol. 19, pages 2716 - 21
    - PUPPE ET AL., J CLIN VIROL, (2004), vol. 30, pages 165 - 74
    - LEARY ET AL., J CLIN MICROBIOL, (2002), vol. 40, pages 1368 - 75
    - MAERTZDORF ET AL., J CLIN MICROBIOL, (2004), vol. 42, pages 981 - 6
    - ERDMAN ET AL., J CLIN MICROBIOL, (2003), vol. 41, pages 4298 - 303
    - MOSQUERA MDEL ET AL., J CLIN MICROBIOL, (2002), vol. 40, pages 111 - 6
    - DEFFERNEZ ET AL., J CLIN MICROBIOL, (2004), vol. 42, pages 3212 - 3218
    - COIRAS ET AL., JMED VIROL, (2004), vol. 72, pages 484 - 95
    - REID ET AL., J VIROL METHODS, (2004), vol. 116, pages 169 - 76
    - POON ET AL., J CLIN VIROL, (2004), vol. 30, pages 214 - 7
    - CAMPSALL ET AL., J CLIN MICROBIOL, (2004), vol. 42, pages 1409 - 13
    - HUANG ET AL., VET MICROBIOL, (2004), vol. 101, pages 209 - 14
    - MAYALL ET AL., J CLIN PATHOL, (2003), vol. 56, pages 728 - 30
    - WHILEY ET AL., JMED VIROL, (2004), vol. 72, pages 467 - 72
    - HATTERMANN ET AL., XENOTRANSPLANTATION, (2004), vol. 11, pages 284 - 94
    - NOVOA ET AL., VET RES, (1995), vol. 26, pages 493 - 8
    - BLAKE ET AL., J CLIN MICROBIOL, (1995), vol. 33, pages 835 - 9
    - HUCKRIEDE ET AL., METHODS ENZYMOL, (2003), vol. 373, pages 74 - 91
    - GREENBAUM ET AL., VACCINE, (2004), vol. 22, pages 2566 - 77
    - ZURBRIGGEN ET AL., EXPERT REV VACCINES, (2003), vol. 2, pages 295 - 304
    - PIASCIK, JAM PHARM ASSOC (WASH DC, (2003), vol. 43, pages 728 - 30
    - MANN ET AL., VACCINE, (2004), vol. 22, pages 2425 - 9
    - HALPERIN ET AL., AM JPUBLIC HEALTH, (1979), vol. 69, pages 1247 - 50
    - HERBERT ET AL., JINFECT DIS, (1979), vol. 140, pages 234 - 8
    - CHEN ET AL., VACCINE, (2003), vol. 21, pages 2830 - 6
    - HEHME ET AL., VIRUS RES, (2004), vol. 103, pages 163 - 71
    - COOPER ET AL., VACCINE, (2004), vol. 22, pages 3136 - 43
    - FREY ET AL., VACCINE, (2003), vol. 21, pages 4234 - 7
    - BOZKIR; HAYTA, DRUG TARGET, (2004), vol. 12, pages 157 - 64
    - GUEBRE-XABIER ET AL., J VIROL, (2003), vol. 77, pages 5218 - 25
    - PEPPOLONI ET AL., EXPERT REV VACCINES, (2003), vol. 2, pages 285 - 93
    - PINE ET AL., J CONTROL RELEASE, (2002), vol. 85, pages 263 - 70
    - BALDRIDGE ET AL., VACCINE, (2000), vol. 18, pages 2416 - 25
    - BANZHOFF, IMMUNOLOGY LETTERS, (2000), vol. 71, pages 91 - 96
    - ADAMSON, DEV BIOL STAND, (1998), vol. 93, pages 89 - 96
    - GOOSSENS ET AL., ARTHRITIS RHEUM, (2001), vol. 44, pages 570 - 7
    - FALLAUX ET AL., HUM GENE THER, (1998), vol. 9, pages 1909 - 17
Opposition   - Anonymous, "Substances of human or animal origin for pharmeutical use", Pharmeuropa, (20030400), vol. 15, no. 2, page 352, XP055326166
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.